Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983;79(2-3):278-83.
doi: 10.1007/BF00427827.

Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system

Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system

C Spyraki et al. Psychopharmacology (Berl). 1983.

Abstract

The rewarding properties of systemically administered heroin were investigated with a conditioned place-preference paradigm. Reinforcing effects were observed with all doses of heroin tested (0.5, 1.0, 2.0 mg/kg) as indicated by a significant increase in preference for the place paired with drug injections. No similar change in preference was observed following saline injections. The rewarding effect of heroin (2 mg/kg) was attenuated by pretreatment with haloperidol (0.2 mg/kg), but haloperidol alone did not produce a place aversion. Lesions induced by 6-hydroxydopamine (6-OHDA) of the mesolimbic dopaminergic pathway at the level of the nucleus accumbens also attenuated the heroin-induced place preference. In contrast, depletion of central and peripheral noradrenaline induced by 6-OHDA had no significant effect on heroin-induced place preference. These data suggest an important role for the mesolimbic DA system in mediating the reinforcing effects of heroin.

PubMed Disclaimer

References

    1. Eur J Pharmacol. 1978 Nov 15;52(2):209-14 - PubMed
    1. Pharmacol Biochem Behav. 1980 Oct;13(4):501-5 - PubMed
    1. Brain Res. 1982 Jul 8;243(1):107-17 - PubMed
    1. Res Commun Chem Pathol Pharmacol. 1975 Sep;12(1):17-24 - PubMed
    1. Eur J Pharmacol. 1979 Nov 16;59(3-4):307-10 - PubMed

Publication types

LinkOut - more resources